March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 24, 2026

Artificial Tears Reduce Dryness Symptoms in 1-Month Study

Prospective multicenter study without a control group shows symptom scores reduced by more than half after 4 weeks of treatment

Conexiant

March 11, 2026

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Conexiant

March 05, 2026

Metformin’s Potential Role in PCO

Common diabetes therapy reaches intraocular lens tissue and may help limit posterior capsule opacification, says newly published data

Conexiant

March 02, 2026

Staging and Practical Management of Diabetic Retinopathy

Approximately half of patients who have severe NPDR and nearly 75% of patients who have very severe NPDR will progress to PDR within 1 year.

Optometric Management

March 01, 2026

Dual-Pathway Gene Therapy for Geographic Atrophy

A new gene therapy approach suggests a potential breakthrough in treating geographic atrophy by combining neuroprotection with complement modulation for more effective vision preservation.

Retinal Physician

June 01, 2014

Indications and Considerations For Chromodissection

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

September 01, 2016

Innovation in Retina

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

October 01, 2016

CODING Q&A

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician